People · Operator
Named in public records as an officer, director or promoter · active 2022–2026 · Biotechnology, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Vaxess Technologies, Inc. | — | Biotechnology | Series C | $138.2M | $269.9M | 2023 |
| Ultivue, Inc. | — | Biotechnology | Series B | $55.2M | $23.4M | 2024 |
| Cellia Science, Inc. | — | Other | Pre-Seed | $250K | $2.1M | 2022 |
Fenel Eloi at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Fenel Eloi on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Keith Crandell | 1 | 11 |
| Calvin Goforth | 1 | 10 |
| Ann DeWitt | 1 | 10 |
| Peter Kolchinsky | 1 | 8 |
| Aaron Sandoski | 1 | 7 |
| Andrea Jackson | 1 | 6 |
| David R. Walt | 1 | 5 |
| Rachel Sha | 1 | 4 |
| Michael Natan | 1 | 3 |
| Peng Yin | 1 | 3 |
| Michael Schrader | 1 | 3 |
| Mark Tracy | 1 | 3 |
| Purnanand Sarma | 1 | 3 |
| Robert Carson | 1 | 3 |
| James Connolly | 1 | 3 |
| Mario Barro | 1 | 3 |
| Andrew Stevenson | 1 | 2 |
| Johannes Fruehauf | 1 | 2 |
| Livio Valenti | 1 | 2 |
| Michael Artinger | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.